Treace Medical Concepts Inc
NASDAQ:TMCI
Treace Medical Concepts Inc
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 248 full-time employees. The company went IPO on 2021-04-23. The firm is focused on strategic product development activities that improve surgical efficiencies and patient outcomes. The firm's proprietary Lapiplasty 3-dimensional (3D) Bunion Correction System, which is a combination of instruments, implants and surgical methods designed to correct all three dimensions of the bunion deformity, address the root cause of the bunion deformity. The Lapiplasty System combines novel surgical approach, the Lapiplasty Procedure, with its procedural instrumentation and single-use implant kits. The Lapiplasty Procedure is designed to rotate the entire metatarsal bone into normal anatomical position in all three dimensions, eliminating the bump and restoring normal anatomy. The Lapiplasty Procedure can be performed in either hospital outpatient or ambulatory surgery center settings. The firm's brands include Lapiplasty, Fast Grafter and Plantar Python.
Treace Medical Concepts, Inc. engages in the design, manufacture, and marketing of orthopedic medical devices and biologic solutions. The company is headquartered in Ponte Vedra, Florida and currently employs 248 full-time employees. The company went IPO on 2021-04-23. The firm is focused on strategic product development activities that improve surgical efficiencies and patient outcomes. The firm's proprietary Lapiplasty 3-dimensional (3D) Bunion Correction System, which is a combination of instruments, implants and surgical methods designed to correct all three dimensions of the bunion deformity, address the root cause of the bunion deformity. The Lapiplasty System combines novel surgical approach, the Lapiplasty Procedure, with its procedural instrumentation and single-use implant kits. The Lapiplasty Procedure is designed to rotate the entire metatarsal bone into normal anatomical position in all three dimensions, eliminating the bump and restoring normal anatomy. The Lapiplasty Procedure can be performed in either hospital outpatient or ambulatory surgery center settings. The firm's brands include Lapiplasty, Fast Grafter and Plantar Python.
Revenue: Treace Medical reported Q3 revenue of $50.2 million, up 11% year-over-year.
Profitability: Adjusted EBITDA loss improved 49% from last year, but net loss increased 6% to $16.3 million.
Guidance Lowered: Full-year 2025 revenue guidance was revised down to $211–213 million, reflecting just 1% to 2% growth.
Product Mix Shift: Growth in new, lower-priced bunion systems offset declining Lapiplasty volumes, impacting overall revenue.
Demand Headwinds: Softer consumer sentiment and deferrals of elective surgeries contributed to lower case volumes.
Distributor Dynamics: Q3 benefited from $6 million in stocking distributor sales, with $3 million pulled forward from future quarters, creating a Q4 headwind.
Cost Actions: Management is focused on controlling costs, improving profitability, and reducing cash burn heading into 2026.
